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PURPOSE. To longitudinally characterize structural retinal changes in achromatopsia (ACHM)
over extended follow-up.
METHODS. Fifty molecularly confirmed ACHM subjects underwent serial spectral-domain
optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF) imaging. Foveal
structure on SD-OCT was graded and compared for evidence of progression, and foveal total
retinal thickness (FTRT) and outer nuclear layer (ONL) thickness were serially measured. FAF
patterns were characterized and compared over time.
RESULTS. Mean SD-OCT follow-up was 61.6 months (age range at baseline, 6–52 years). Forty-
five of the subjects had serial FAF (mean follow-up: 48.5 months). Only 6 (12%) of the subjects
demonstrated qualitative change on serial foveal SD-OCT scans. Among the entire cohort,
there was no statistically significant change over time in FTRT (P ¼ 0.2459) or hyporeflective
zone (HRZ) diameter (P ¼ 0.3737). There was a small—but statistically significant—increase
in ONL thickness (P ¼ 0.0084). Three different FAF patterns were observed: centrally
increased FAF (13/45), normal FAF (14/45), and well-demarcated reduced FAF (18/45), with
the latter group displaying a small gradual increase in the area of reduced FAF of 0.055 mm2
over 43.4 months (P ¼ 0.0011).
CONCLUSIONS. This longitudinal study of retinal structure in ACHM represents the largest
cohort and longest follow-up period to date. Our findings support the presiding notion that
ACHM is essentially a stationary condition regarding retinal structure, and any change over
time is likely to be small, slow, and variable across patients. This may potentially afford a wider
window for therapeutic intervention.
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Achromatopsia (ACHM) is an autosomal recessive conedysfunction disorder affecting approximately one in
30,000 live births worldwide1,2 and is characterized by lack
of function of all three classes of cone photoreceptor. Six
causative genes are considered responsible for over 90% of
cases: CNGA3, CNGB3, GNAT2, PDE6H, PDE6C, and ATF6.3
Affected individuals display marked photophobia and pendular
nystagmus from birth or early infancy, associated with reduced
visual acuity, deficient or absent color vision, and central
scotomata.4 At present, there are no curative treatments
available, with current management aiming to minimize the
effects of symptoms and optimize residual visual function.
However, promising results from studies investigating gene-
replacement therapy to restore cone function in animal models
with ACHM has led to the recent establishment of a number of
human clinical trials, evaluating the safety and efficacy of gene
supplementation in ACHM.4 Assessment of retinal structure and
knowledge of the natural history of ACHM is key to identifying
subjects potentially suitable for this intervention and also for
subsequently monitoring the effects of treatment.
ACHM has classically been described as a stationary
condition. Sundaram et al.5 evaluated 40 individuals with
ACHM aged between 6 and 52 years, and found no significant
correlation of deterioration in visual acuity, contrast sensitivity,
or reading acuity with advancing age. Optical coherence
tomography (OCT) has demonstrated variable outer retinal
structure at the central macula, including at the level of the
photoreceptor inner segment ellipsoid layer (ISe) and retinal
pigment epithelium (RPE).5–8 In their study, Sundaram et al.5
found that the variable spectral-domain OCT (SD-OCT)
appearances did not correlate with age or genotype and that
total foveal retinal thickness (FTRT), foveal outer nuclear layer
(ONL) thickness, and ISe intensity were not age-dependent.
Given these results supporting a stationary natural history, the
authors purported that there may potentially be a wide window
of opportunity for therapeutic intervention. In contrast, other
work has alluded to progressive cone photoreceptor loss in
ACHM.6–8 However, these studies have often been limited by
their cross-sectional nature and small sample size. To address
this, a larger prospective structural and functional ACHM study
(n¼38) has been conducted by Aboshiha et al.9 with the aim of
performing statistical analysis on the data acquired to draw
more definitive conclusions about the frequency and rate of any
disease progression. The authors reported essentially stable SD-
OCT findings over time. There is a relative paucity of studies
investigating fundus autofluorescence (FAF) in ACHM and, in
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particular, over time.10 Therefore, Aboshiha et al. 9 additionally
investigated this parameter. The authors concluded that the
retinal parameters they assessed either remained stable or
changed minimally in a small proportion of patients. However,
it is not inconceivable that monitoring patients over a longer
period may identify a greater proportion of individuals who
develop progressive changes. Since an understanding of the
natural history of ACHM is key to the planning and selection of
appropriate candidates for such therapeutic interventions as
gene therapy, we have performed serial assessment of SD-OCT
and FAF in a longitudinal study of subjects with molecularly
proven ACHM, with a larger cohort size and longer follow-up
duration than previously conducted.9 Our aim was to further
examine structural progression in ACHM, thereby making
inferences about the optimal timing for treatment.
METHODS
Subjects
Fifty subjects with ACHM, characterized phenotypically and
genotypically, were prospectively seen between 32 and 86
months after baseline assessment. All subjects were partici-
pants of the ACHM natural history study conducted at
Moorfields Eye Hospital. The study protocol adhered to the
tenets of the Declaration of Helsinki and was approved by the
Moorfields Eye Hospital Ethics Committee. Informed consent
was obtained from all subjects prior to their entry to the study.
Clinical Assessments
Best-corrected visual acuity (BCVA) and contrast sensitivity
were measured at baseline and follow-up assessments using an
Early Treatment Diabetic Retinopathy Study chart and Pelli-
Robson chart at 1 meter, respectively.
Spectral-Domain OCT (SD-OCT)
SD-OCT imaging was performed on both eyes following
pupillary dilation with tropicamide 1% and phenylephrine
2.5% eye drops. Line and volume scans were acquired with the
Spectralis device (Heidelberg Engineering, Inc., Heidelberg,
Germany) using the same protocol as that employed by
Aboshiha et al.9 At follow-up visits, the device was switched to
follow-up mode so the same scanning location was used both
at baseline and follow-up. This enabled comparable measure-
ments to be made between the two visits for a given subject
but may not have been entirely possible in individuals with
significant nystagmus. The transverse scale of each image was
calculated using the axial length of the corresponding eye. This
was measured using the Zeiss IOL Master (Carl Zeiss Meditec,
Inc., Jena, Germany).
Qualitative assessment of foveal structure was performed by
grading SD-OCT images into one of five categories: (1)
continuous ISe, (2) ISe disruption, (3) ISe absence, (4)
presence of an HRZ, or (5) outer retinal atrophy. For each
subject, both right and left eyes were graded at baseline and
follow-up. Consensus grading was established by three
independent observers (NH, MG, and MM). Measurements of
FTRT (internal limiting membrane to RPE distance), foveal
ONL thickness and, where applicable, HRZ diameter at
baseline and follow-up were made, as in the previous
longitudinal study.9 All measurements were made by a single
examiner (NH) using the digital calipers built into the software
(Heidelberg Eye Explorer; Heidelberg Engineering), and a 1-
pixel:1-lm display with maximum magnification. Where
appropriate, measurements were corrected for axial length
by normalizing relative to the average axial length of a healthy
adult human eye. The mean of three measurements was
calculated and recorded for each parameter in each subject and
at each visit. The presence/absence of foveal hypoplasia was
also noted, defined as the persistence of one or more inner
retinal layers (outer plexiform layer, inner nuclear layer, inner
plexiform layer or ganglion cell layer) through the fovea.5
Fundus Autofluorescence (FAF)
FAF imaging was performed bilaterally at baseline and follow-
up, as per the protocol utilized by Aboshiha et al.9 Briefly,
assessments were performed using the AF mode on the
Spectralis device (Heidelberg Engineering) following pupillary
dilation as previously described and after SD-OCT image
acquisition. In subjects displaying a well-demarcated region
of reduced autofluorescence at both visits, the area was
measured by tracing around the circumference of the hypo-
autofluorescent region with a mouse-driven cursor and
recording the area within, as calculated by the in-built image
analysis software (Heidelberg Eye Explorer; Heidelberg Engi-
neering). All FAF measurements were made by the same
examiner (NH). For each FAF image, the mean of three area
measurements was calculated and used for further analysis.
Data Analysis Methods
The D’Agostino-Pearson Omnibus Test was used to verify the
normality of data before using any parametric tests. The
distribution of FTRT, ONL thickness, and HRZ diameter values
did not demonstrate normality; therefore, nonparametric tests
were used throughout for statistical analysis. Statistical tests
were performed using GraphPad Prism, version 5 (GraphPad
Software, Inc., La Jolla, CA, USA). Qualitative changes in
foveal structure on SD-OCT were evaluated in both eyes for
each subject. Sundaram et al.5 found no significant differences
in measured parameters between the two eyes of subjects in
their cross-sectional study of ACHM, and therefore selected
the left eye for further quantitative analysis; this was
replicated by Aboshiha et al.9 in their subsequent longitudinal
study. In keeping with these previous studies, we also utilized
the left eye for more detailed analysis of quantitative
parameters.
RESULTS
Fifty patients with greater than 24 months follow-up who had
interpretable transfoveal SD-OCT scans at baseline and follow-
up were included in the study. Twenty-six patients were male
(52%) and 24 were female (48%). The mean age of the cohort
at baseline was 23.9 years (range, 7–52 years). Forty-five
subjects (90%) had baseline and follow-up FAF. Of these 50
subjects, 32 had previously been described by Sundaram et al.5
Table 1 summarizes the age at baseline, follow-up interval, and
structural parameters in our cohort over time. Supplementary
Table S1 cross-references our subjects to those included in the
study by Sundaram et al.5 and demonstrates the detailed
genotype of each patient. Supplementary Table S2 shows the
absolute FTRT and ONL measurements for the left eye of each
subject, at baseline and follow-up.
SD-OCT
Comparable foveal SD-OCT scans were obtained at baseline
and follow-up in all 50 subjects. Six of these subjects (12%)
showed qualitative progression bilaterally on SD-OCT between
baseline and follow-up. Patients 2, 24, 37, and 38 progressed
from category 1 (continuous ISe layer) at baseline to category 2
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(ISe disruption) over 64-, 42-, 52-, and 59-month follow-up
periods, respectively. Patients 15 and 30 progressed from
category 2 (ISe disruption) at baseline to category 4 (HRZ) at
follow-up, over 69- and 66-month periods, respectively (Fig. 1).
In the remaining 44 subjects, SD-OCT grade was identical
bilaterally at baseline and remained unchanged in both eyes at
follow-up. Thus, there was no evidence of qualitative
progression in these subjects (Fig. 2).
Thirty-seven subjects (74%) showed foveal hypoplasia
bilaterally at baseline, and no change in the presence or
absence of this feature in either eye was found between
baseline and follow-up in any patient.
TABLE 1. Summary of Patient Characteristics and Clinical Findings
Patient
No.
Age at
Baseline,
y Genotype
SD-OCT
f/u
Interval,
mo
SD-OCT
Category
b f/u
Change
in FTRT
Between
Assessments,
lm
Change
in ONL
Thickness
Between
Assessments,
lm
Change
in HRZ
Diameter
Between
Assessments,
lm
FAF f/u
Interval,
mo
Central
FAF
Pattern
at Both
Assessments
Change
in Area
of
Reduced
FAF,
mm2
Foveal
Hypoplasia?
1 10 CNGA3 39 3 3 þ3 þ2 n/a no f/u n/a n/a Yes
2 10 CNGA3 64 1 2 þ7 þ5 n/a 37 Normal n/a Yes
3 11 CNGA3 58 1 1 þ9 þ8 n/a 54 Reduced 0 Yes
4 11 CNGA3 55 2 2 6 7 n/a 55 Increased n/a No
5 17 CNGA3 63 4 4 7 7 þ237 51 Reduced þ0.01 Yes
6 19 CNGA3 68 2 2 0 2 n/a 14 Reduced 0 No
7 22 CNGA3 66 2 2 3 4 n/a 14 Normal n/a Yes
8 21 CNGA3 67 4 4 2 4 þ150 51 Normal n/a Yes
9 24 CNGA3 74 4 4 2 1 þ25 74 Normal n/a Yes
10 25 CNGA3 60 5 5 5 n/a n/a 60 Reduced þ0.2 Yes
11 30 CNGA3 53 3 3 þ4 3 n/a 53 Reduced þ0.02 Yes
12 29 CNGA3 67 4 4 4 7 140 36 Reduced þ0.03 Yes
13 31 CNGA3 73 4 4 þ4 þ4 þ43 62 Increased n/a Yes
14 34 CNGA3 73 2 2 þ5 þ3 n/a no f/u n/a n/a Yes
15 35 CNGA3 69 2 4 10 8 n/a 45 Normal n/a No
16 8 CNGA3 55 2 2 1 2 n/a 45 Increased n/a No
17 32 CNGA3 76 2 2 6 6 n/a 19 Reduced þ0.01 Yes
18 46 CNGA3 57 4 4 þ2 þ2 þ4 58 Reduced þ0.01 Yes
19 30 CNGA3 86 4 4 7 5 þ21 76 Normal n/a No
20 8 CNGA3 62 1 1 10 10 n/a 62 Increased n/a No
21 10 CNGB3 81 4 4 þ5 þ6 þ59 38 Reduced þ0.03 Yes
22 11 CNGB3 54 2 2 1 3 n/a 54 Increased n/a Yes
23 12 CNGB3 66 3 3 3 2 n/a 66 Increased n/a Yes
24 12 CNGB3 70 2 2 þ1 2 n/a 70 Normal n/a Yes
25 13 CNGB3 68 1 1 þ2 1 n/a 54 Increased n/a No
26 18 CNGB3 71 4 4 þ3 þ2 91 36 Reduced þ0.01 Yes
27 18 CNGB3 66 4 4 þ1 3 22 59 Increased n/a Yes
28 22 CNGB3 74 5 5 9 n/a n/a 23 Reduced þ0.06 Yes
29 26 CNGB3 48 1 1 4 3 n/a 48 Increased n/a No
30 33 CNGB3 66 2 4 þ9 8 n/a 19 Reduced þ0.01 Yes
31 47 CNGB3 63 4 4 2 4 4 31 Reduced þ0.02 No
32 15 CNGB3 32 2 2 þ5 þ4 n/a 32 Normal n/a Yes
33 23 CNGB3 62 3 3 3 4 n/a no f/u n/a n/a Yes
34 26 CNGB3 42 1 2 þ3 þ5 n/a 42 Reduced þ0.06 Yes
35 26 CNGB3 43 2 2 0 þ4 n/a 43 Reduced 0 Yes
36 29 CNGB3 38 2 2 4 1 n/a 26 Normal n/a No
37 25 CNGB3 52 1 2 þ2 2 n/a 52 Increased n/a Yes
38 7 CNGB3 59 1 2 4 5 n/a no f/u n/a n/a No
39 35 CNGB3 73 2 2 4 4 n/a 73 Increased n/a Yes
40 7 CNGB3 57 2 2 þ4 þ1 n/a 5 Normal n/a Yes
41 29 CNGB3 39 2 2 0 1 n/a 39 Normal n/a Yes
42 18 CNGB3 42 1 1 þ1 3 n/a 42 Normal n/a Yes
43 12 CNGB3 48 3 3 3 1 n/a 14 Normal n/a Yes
44 43 GNAT2 79 1 1 4 3 n/a 79 Reduced þ0.05 No
45 52 GNAT2 79 1 1 3 3 n/a 129 Normal n/a No
46 43 PDE6C 79 5 5 3 n/a n/a 104 Reduced þ0.47 Yes
47 19 ATF6 75 3 3 1 5 n/a 46 Increased n/a Yes
48 23 ATF6 70 3 3 0 6 n/a 70 Increased n/a Yes
49 44 ATF6 54 3 3 9 5 n/a 21 Reduced 0 Yes
50 44 ATF6 44 4 4 þ3 4 þ54 no f/u n/a n/a Yes
n/a, not applicable;þ, increase in metric over time;, decrease in metric over time.
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FTRT, ONL Thickness and HRZ Diameter
FTRTwas measured in all 50 subjects at baseline and follow-up.
Mean change in absolute FTRT (i.e., FTRT at follow-up minus
FTRT at baseline) was 0.94 lm (range, 10 to þ9 lm). The
change in absolute FTRT between visits in the cohort was not
statistically significant (Wilcoxon signed-rank test; P¼ 0.2459).
Mean percentage change in FTRT between baseline and follow-
up was 0.98% (range, 8.55% to þ6.12%). The percentage
change in FTRT within the cohort was also not statistically
significant (Wilcoxon signed-rank test; P¼ 0.0732). There was
no significant correlation between age and change in FTRT
(Spearman’s correlation coefficient¼0.17; P¼0.2336). There
was, however, a positive correlation between starting FTRT
and change in FTRT, where subjects with a lower FTRT at
baseline showed greater reduction over time (Spearman’s
correlation coefficient ¼ 0.41; P ¼ 0.0029). This suggests that
the less the initial FTRT, the greater the degree of central
retinal thinning over time.
Three (8%) of the 37 subjects with foveal hypoplasia
(patients 10, 28, and 46) did not have a structurally distinct
ONL that could be accurately measured and were excluded
from ONL thickness analysis. The mean change in absolute
ONL thickness in the remaining 47 subjects (i.e., ONL
thickness at follow-up minus ONL thickness at baseline) was
þ1.98 lm (range,10 toþ8 lm). This change was statistically
significant between assessments (Wilcoxon signed-rank test; P
¼ 0.0084). Mean percentage change in ONL thickness between
baseline and follow-up was þ2.19% (range, 14.29% to
þ8.08%). The percentage change in ONL thickness within the
cohort was also statistically significant (Wilcoxon signed-rank
test; P ¼ 0.0031).
Five of the 12 patients who had an HRZ at both baseline and
follow-up had a starting absolute FTRT greater than the average
of the entire cohort. There was no statistically significant
change in the diameter of the HRZ over a mean follow-up
interval of 67 months among these 12 patients (Wilcoxon
signed-rank test; P ¼ 0.3737). Mean change in absolute FTRT
FIGURE 1. Longitudinal SD-OCT imaging of ACHM cases with structural changes. The left column shows baseline transfoveal SD-OCT imaging and
the right column shows follow-up images over the same location. Themiddle column depicts33 magnification of the foveal ellipsoid zone from the
corresponding SD-OCT (white arrows). Both subjects (A) and (B), with 69 and 66 months of follow-up, respectively, progressed from category 2
(disrupted ISe layer) to category 4 (presence of HRZ) bilaterally. BS, baseline; FU, follow-up; yo, years old. Scale bar: 200 lm.
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within this smaller cohort was0.50 lm (range,7 toþ5 lm),
that is, smaller than the mean reduction in absolute FTRT
noted in the entire cohort over time.
Figure 3 demonstrates the range of changes in structural
parameters, observed over time within our cohort.
FAF
Forty-five subjects (90%) had baseline and follow-up FAF (Table
1). As in the study by Aboshiha et al.,9 three distinct FAF
patterns were observed in our subjects at baseline: (1) a
normal FAF pattern, seen in 14 patients (31%); (2) an abnormal
FIGURE 2. Longitudinal SD-OCT imaging of stationary ACHM cases. The left column shows baseline transfoveal SD-OCT imaging and the right
column shows follow-up images over the same location. The middle column depicts 33 magnification of the foveal ellipsoid zone from the
corresponding SD-OCT (white arrows). Five subjects (A–E) with five different ACHM genotypes (GNAT2, CNGA3, CNGB3, ATF6, PDE6C) and five
different categories of SD-OCT, respectively, showed no structural change over a follow-up period of 54 to 86 months, with an age range at baseline
of 11 to 52 years old. Scale bar: 200 lm.
Longitudinal Review of Retinal Structure in Achromatopsia IOVS j December 2018 j Vol. 59 j No. 15 j 5739
Downloaded From: https://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/937686/ on 12/11/2018
central increase in FAF, seen in 13 patients (29%); and (3) a
well-demarcated central reduction in FAF, seen in 18 patients
(40%). No subject demonstrated a change in FAF pattern over
time. The area of reduced FAF was measured at baseline and
follow-up in those individuals demonstrating this phenotype,
since this feature was amenable to quantification. Ten of these
subjects had a starting absolute FTRT smaller than the average
of the entire cohort. Mean increase in the area of reduced FAF
was 0.055 mm2, over a mean follow-up interval of 43 months.
The change in FAF between baseline and follow-up was
statistically significant (Wilcoxon signed-rank test; P¼ 0.0011).
Mean change in absolute FTRT within the 18 subjects
demonstrating reduced FAF was 0.78 lm (range, 9 to þ9
lm), smaller than the mean reduction in absolute FTRT noted
in the entire cohort over time.
Genotype-Phenotype Correlation
CNGA3 and CNGB3 subgroups were analyzed separately, and
no statistically significant difference was noted between the
two cohorts regarding change in FTRT (Mann-Whitney U test;
P¼0.5187) or change in ONL thickness (Mann-Whitney U test;
P ¼ 0.5986). Comparisons could not be made with GNAT2,
PDE6C, and ATF6 subgroups, given the small numbers of
individuals within these groups. Similarly, statistical compari-
sons could not be made between CNGA3 and CNGB3
FIGURE 3. Longitudinal SD-OCT imaging and retinal structure measurements. The left column shows baseline transfoveal SD-OCT imaging and the
right column shows follow-up images over the same location for five subjects (A–E). ONL thickness is marked with orange lines. Subject (B) had the
greatest HRZ width increase in the cohort. Subject (C) had a minimal change in HRZ width. In (A, B, D), a change was identified in the ONL
thickness (7–10 lm); in contrast with (C, E) in whom there was no significant difference. Scale bar: 200 lm.
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subgroups regarding change in HRZ diameter and area of
reduced FAF, again due to small sample sizes.
BCVA and Contrast Sensitivity
Table 2 displays the BCVA and contrast sensitivities of the
subjects at baseline and follow-up. For consistency, only data
from the left eye were analyzed. The mean BCVA at baseline
was 0.91 logMAR (range, 0.68–1.32 logMAR), and this was
significantly different from the mean BCVA at follow-up, which
measured 0.87 logMAR (range, 0.60–1.20 logMAR; paired t-test;
P ¼ 0.014). However, the mean of the logarithm of contrast
sensitivity (logCS) at baseline of 1.16 logCS (range, 0.5–1.55
logCS) was not significantly different from that measured at
follow-up of 1.15 logCS (range, 0.25–1.65 logCS; paired t-test; P
¼ 0.681), where higher logCS values indicate better contrast
sensitivity.
DISCUSSION
The natural history of ACHM has been the center of some
debate, with several studies suggesting it is a progressive
TABLE 2. Summary of BCVA and Contrast Sensitivity at Baseline and Follow-up
Patient
No.
Age at
Baseline, y Genotype
SD-OCT f/u
Interval, mo
BCVA,
logMAR b f/u
Contrast Sensitivity,
logCS b f/u
1 10 CNGA3 39 0.86 0.72 1.40 1.35
2 10 CNGA3 64 0.80 0.78 1.25 1.35
3 11 CNGA3 58 1.08 0.96 0.90 1.30
4 11 CNGA3 55 0.94 0.90 1.05 n/a
5 17 CNGA3 63 0.88 0.76 1.20 1.20
6 19 CNGA3 68 0.80 1.02 0.65 0.25
7 22 CNGA3 66 1.16 1.16 1.05 0.90
8 21 CNGA3 67 0.92 0.84 1.35 1.30
9 24 CNGA3 74 0.86 0.90 1.35 1.30
10 25 CNGA3 60 0.84 0.80 1.35 n/a
11 30 CNGA3 53 0.76 0.72 1.55 1.30
12 29 CNGA3 67 0.74 0.76 1.20 1.35
13 31 CNGA3 73 0.90 0.90 1.45 1.15
14 34 CNGA3 73 0.90 0.82 1.20 1.40
15 35 CNGA3 69 0.96 0.96 1.00 1.05
16 8 CNGA3 55 1.00 0.90 1.05 n/a
17 32 CNGA3 76 0.84 0.74 1.25 1.35
18 46 CNGA3 57 0.80 0.70 1.30 1.45
19 30 CNGA3 86 1.00 0.80 n/a 1.20
20 8 CNGA3 62 1.00 1.02 n/a 1.05
21 10 CNGB3 81 0.82 0.82 1.05 0.85
22 11 CNGB3 54 0.90 0.82 1.35 1.35
23 12 CNGB3 66 0.90 0.92 1.00 1.05
24 12 CNGB3 70 0.76 0.76 1.30 1.45
25 13 CNGB3 68 0.90 0.84 1.30 1.35
26 18 CNGB3 71 0.74 0.70 1.25 1.20
27 18 CNGB3 66 0.86 0.76 1.35 1.35
28 22 CNGB3 74 0.76 0.86 1.25 1.05
29 26 CNGB3 48 0.90 0.82 1.45 1.40
30 33 CNGB3 66 0.96 0.84 0.90 1.00
31 47 CNGB3 63 0.96 0.98 1.10 0.95
32 15 CNGB3 32 0.84 0.60 1.55 1.40
33 23 CNGB3 62 0.96 1.06 1.00 0.95
34 26 CNGB3 42 1.00 1.04 0.70 0.30
35 26 CNGB3 43 0.84 0.92 1.10 1.00
36 29 CNGB3 38 0.84 0.76 1.35 1.20
37 25 CNGB3 52 0.92 0.94 1.20 1.40
38 7 CNGB3 59 1.04 1.02 0.90 1.10
39 35 CNGB3 73 1.10 1.08 1.10 0.85
40 7 CNGB3 57 1.04 0.92 0.80 1.15
41 29 CNGB3 39 0.92 0.88 1.35 1.35
42 18 CNGB3 42 0.68 0.82 1.40 1.00
43 12 CNGB3 48 0.88 0.88 1.30 1.00
44 43 GNAT2 79 1.10 1.04 0.70 0.85
45 52 GNAT2 79 1.00 1.20 0.50 0.75
46 43 PDE6C 79 1.32 0.94 1.05 1.10
47 19 ATF6 75 0.96 0.90 1.45 1.35
48 23 ATF6 70 0.86 0.74 1.20 1.35
49 44 ATF6 54 1.04 0.94 1.10 1.15
50 44 ATF6 44 0.70 0.74 1.30 1.65
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condition. Thiadens et al.6 investigated 40 subjects with
achromatopsia cross-sectionally with SD-OCT and proposed
that cone cell decay began in early childhood, with retinal
thinning correlating with age. Thomas et al.8 found in their
study of 13 individuals with ACHM that the presence of a HRZ
and ONL thinning were also age-dependent. However, a
significant limitation of these studies is their cross-sectional
nature. To identify cone loss over time, there is a need for
longitudinal assessment.
Thomas et al. followed 8 subjects with ACHM over a mean
period of 16 months.7 They found that the 5 younger subjects
(<10 years) showed progressive morphological ISe changes
between visits 1 and 2. However, the three older subjects (aged
over 40 years) did not show any changes. They concluded that
dynamic retinal changes in younger patients provided evidence
that ACHM is a progressive disorder. However, due to the small
sample size, the group was unable to statistically evaluate the
significance of the reported changes. Aboshiha et al.9 sought to
address this with their longitudinal investigation of 38 subjects
with ACHM. They reported retinal structure to be largely stable
over time regarding SD-OCT. Only 2 subjects showed
qualitative evidence of progression, as evidenced by advancing
OCT grade bilaterally. There was no statistically significant
change in the quantitative SD-OCT parameters assessed, for
instance, FTRT and ONL thickness. Furthermore, there was no
statistically significant change in HRZ diameter in the 9
subjects with an HRZ at baseline and follow-up visits. With
regard to FAF, Aboshiha and colleagues did not observe a
change in FAF pattern between baseline and follow-up visits, or
between eyes, in the 30 subjects for whom this parameter
could be assessed.9 In those subjects with a reduced FAF
pattern at baseline and follow-up (n ¼ 15), a small but
statistically significant reduction in the median area of reduced
FAF was noted between visits. However, the mean follow-up
period of their cohort was 19.5 months (range, 13–24 months),
and it is possible that retinal change may occur over longer
periods.
More recently, and consistent with our data, Triantafylla et
al. reported no changes in FTRT and only minor changes in
ONL thickness in their study of 10 subjects with ACHM, with a
mean follow-up period of 65.9 months (Triantafylla et al., IOVS
2018;59:ARVO E-Abstract 5205). However, they reported a 2.5-
fold increase in HRZ width, which we did not observe in our
data. Interestingly, 6 of their 10 patients were children under
the age of 10, while 7 of our 50 subjects were 10 years old or
younger. Thus, we cannot rule out the idea that there is some
progression very early in the disease that stabilizes later in the
first decade. Consistent with this, the 2 subjects in our study
with the greatest ONL thickness change were 10 and 11 years
of age. This highlights the need to begin natural history studies
in even younger populations as well as the availability of
handheld OCT as useful in these efforts.11
To our knowledge, our work represents the largest
longitudinal study of retinal structure in ACHM. The large
patient sample size allows for statistical analysis of the
significance of any change over time. Our cohort showed no
statistically significant change in FTRT over time nor in HRZ
diameter in those subjects where this feature was present at
the baseline assessment. This is consistent with the results of
the longitudinal study undertaken by Aboshiha et al.9 and
supports the notion that ACHM is a predominantly stable
condition with regard to retinal structure. The increase in ONL
thickness over time was statistically significant. However, this
change was small (less than 2 lm on average). Thus, while the
change in this parameter may be statistically significant, its
clinical relevance is questionable. Indeed, retinal thickness has
been shown to change with age. Nieves-Moreno et al.12
reported a reduction in retinal thickness for each year of
increased age in healthy subjects, concluding that the
thickness of most retinal layers varies with age. Our
measurements of change in retinal thickness are within those
expected for normal aging, suggesting that they do not
represent true disease progression.
With regard to qualitative analysis, 6 subjects (12%) showed
evidence of progression to higher (i.e., worse) SD-OCT grades.
Similar changes were noted in both eyes, suggesting that this
likely represented real disease progression. Two of these
subjects were of the CNGA3 genotype and 4 were CNGB3,
suggesting that qualitative progression may be an uncommon
feature of both these most frequent genotypes. The mean age
of these subjects was 20.3 years (range, 7–35 years), and mean
SD-OCT follow-up interval was 63.6 months (range, 52–70
months). These values are not dissimilar to those of the entire
cohort, which had a mean age at baseline of 23.9 years and
mean SD-OCT follow-up interval of 61.6 months. Therefore, it
would seem unlikely that age at baseline and duration of
follow-up are factors that influence any qualitative progression
observed on SD-OCT. Interestingly however, these subjects
displaying qualitative category progression did not display a
reduction in FTRT or ONL thickness of greater than 10 lm, and
indeed some subjects who demonstrated more thinning
quantitatively did not show change in SD-OCT category over
time. Thus, there appears to be a discordance between
quantitative change in terms of retinal thickness and qualitative
change in terms of foveal morphology on SD-OCT. In part, this
may be attributable to a limitation of this study: There are often
difficulties in scanning exactly the same location through the
fovea at each visit for a given patient. The Spectralis SD-OCT
device (Heidelberg Engineering) sets the baseline scan as the
reference scan, and the in-built software attempts to direct the
SD-OCT fixation target to a position that corresponds to the
same retinal location during subsequent image acquisition.
However, this is not always possible in ACHM patients with
severe nystagmus and poor fixation. A follow-up scan may
therefore be centered at a slightly different position, and this
may contribute subtle variations in the quantitative and
qualitative results recorded compared to baseline. This
suggests that there may be a role for collecting multiple
representative scans at baseline.
In showing qualitative change, we reported a higher
proportion of subjects (12%) than did the work of Aboshiha
et al.,9 who described this in 5% of their cohort. However, their
study had a mean follow-up period of only 19.5 months and
fewer subjects (38 compared to our 50). By contrast, the
subjects in our study showing qualitative change all had follow-
up periods of greater than 40 months. Therefore, it may be that
foveal appearances do gradually deteriorate in a small
proportion of patients, given sufficient time. Further work
assessing retinal function in patients who have been followed-
up over extended periods may shed light on any potential
functional consequences of such changes. Aboshiha et al.9
found that patients demonstrating qualitative change did not
show significant associated changes in functional parameters.
SD-OCT changes, however, may predate change in visual
function, and extended follow-up could allow these delayed
functional changes to manifest.
With regard to FAF, we identified three distinct patterns in
our cohort, as per previous work.9,10 The three patterns were
present in relatively equal proportions among our cohort and
did not change in any subject between baseline and follow-up.
In those patients with reduced FAF at baseline, there was a
statistically significant increase in the area of reduced signal
over time; however, this rate of increase was very small (0.015
mm2 per year). This is very similar to the rate of 0.02 mm2 per
year identified by Aboshiha et al.9 A range of retinal
mechanisms can result in variations in the observed FAF
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pattern. Of note, our results show no particular relationship
between the observed pattern of FAF and qualitative SD-OCT
appearances for subjects with SD-OCT categories 1 through 4.
Thus, all three FAF patterns were observed across these
categories. However, all 3 subjects with SD-OCT category 5
scans at baseline and follow-up demonstrated a pattern of
reduced FAF. This is because of the atrophic retinal changes
seen in this SD-OCT phenotype, which in turn are associated
with a reduced density of the fluorophore lipofuscin in the
affected regions. Finer quantitative methods of FAF analysis are
available,13,14 and it may be that further work using these
techniques may identify more subtle changes in FAF patterns.
However, the clinical significance of FAF in ACHM remains
poorly established, and we would predict that any progression
in this parameter is likely to be slow and small in magnitude.
Interestingly, recent work by Matet et al.15 has advocated the
role of near-infrared autofluorescence (NIR-AF) in the investi-
gation of ACHM. While the Spectralis device performs short-
wavelength autofluorescence (SW-AF) imaging, NIR-AF is a less
frequently used imaging modality. In subjects with ACHM, the
authors correlated NIR-AF with SW-AF features and structural
alterations on SD-OCT. Patients with a central hypo-autofluo-
rescence on NIR-AF were older and displayed more advanced
structural abnormalities at the fovea than did those with
normal NIR-AF, while SW-AF was not correlated to other
multimodal findings. This suggests a potential role for NIR-AF
as an imaging biomarker in ACHM.15
In summary, our findings from a larger cohort and longer
follow-up of individuals with ACHM provide further support to
the presiding notion that this is essentially a stable condition
regarding retinal structure and that any change over time is
likely to be small, slow, and occur in only a limited proportion
of patients. Of note, Zein et al.16 recently studied the effect of
ciliary neurotrophic factor (CNTF) in 5 subjects with CNGB3-
ACHM, all of whom had an HRZ on SD-OCT at baseline. CNTF
is thought to have a neurotrophic effect on human cone
photoreceptors. The group demonstrated a sustained filling or
collapse of the HRZ in all treated eyes. They proposed that
CNTF was responsible for the changes in retinal foveal
morphology since they were not seen in untreated eyes. Our
findings lend support to the idea that marked changes in retinal
morphology observed following the therapeutic interventions
tested to date can be attributed to the treatment rather than to
disease progression since we have demonstrated that structural
changes in the natural history are negligible and very slow.
Further work using more detailed imaging techniques, such
as adaptive optics scanning light ophthalmoscopy (AOSLO),
may better demonstrate the earliest indicators of any structural
progression in ACHM.17 AOSLO allows visualization of
individual rod and cone cells in vivo18,19 and has confirmed
the presence of cone photoreceptors in all patients with
ACHM, albeit reduced in number compared to the unaffected
retina, with a wide range of cone densities, and often a
disconnect with SD-OCT appearance.20 With regard to
assessing progression of ACHM with AOSLO, Langlo et al.21
demonstrated that foveal cone structure showed little or no
change in their cohort of patients with CNGB3-ACHM over a
follow-up period of 6 to 26 months. However, extending
follow-up (as in our study of SD-OCT and FAF imaging) may
provide new insights into very gradual retinal changes
occurring at the microscopic level.
Interestingly, while Aboshiha et al.9 demonstrated stability
of functional parameters in conjunction with structural
stability, the results from our cohort show a small but clinically
significant improvement in mean BCVA over time, though no
significant change in contrast sensitivity. The change in BCVA
may partially be explained by the fact that 7 subjects within
our cohort were age 10 years or younger at presentation. In
these individuals, the transition from childhood toward
adulthood over prolonged follow-up may have enabled more
accurate assessment of visual acuity at follow-up, thus leading
to an apparent improvement in this parameter. Furthermore,
nystagmus in children with ACHM may lessen with age.22 The
improved fixation associated with this could potentially lead to
a mild improvement in visual acuity. Nevertheless, while the
increase in BCVA within our cohort over time was statistically
significant, it was small in magnitude and thus likely to be of
minimal clinical significance.
For now, our work suggests that disease progression for the
majority of our cohort is negligible. Thus, there may potentially
be a wide window for therapeutic intervention, and gene
replacement therapy may be a viable option for affected adults
as well as children. However, the functional benefit derived by
older individuals may be limited by abnormal organization of
the visual cortex. Baseler et al.23 described reorganization of
the visual cortex from birth onward in ACHM in response to
abnormal visual experience. The authors attributed this to
visual system plasticity, postulating that this may result from a
range of mechanisms, including reorganization of neural
connectivity and changes in the efficacy of established
connections. Plasticity of the brain is maximal in the first few
years of life, reducing with advancing years.24 Thus, while it is
conceivable that older subjects may show some improvement
following treatment, it is likely that earlier intervention in
children, when anomalous visual processing pathways are less
developed, may yield optimal results. Our work supporting the
largely nonprogressive nature of ACHM is also valuable when
evaluating the effects of potential interventions in a clinical
trial setting. Knowledge of the condition’s relative stability
enables structural and functional changes occurring post-
treatment to be attributed to the intervention rather than to
the natural disease process, allowing for better recognition of
the specific effects of the treatment itself. Indeed, trial
regulatory bodies will often seek evidence confirming the
disease’s stationary nature prior to approving a study, and our
results may aid in the establishment of future interventional
studies for ACHM.
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